TAVR at 5 Years — Rematch or Swan Song for ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
Titre :
TAVR at 5 Years — Rematch or Swan Song for Surgery?
Auteur(s) :
van Belle, Eric [Auteur]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 [RNMCD]
Titre de la revue :
New England Journal of Medicine
Pagination :
867-868
Éditeur :
Massachusetts Medical Society
Date de publication :
2020-02-27
ISSN :
0028-4793
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement ...
Lire la suite >To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement in the long term. Makkar et al. examined this question and report in this issue of the Journal the 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial, 2 which involved patients at intermediate surgical risk. A total of 2032 patients were stratified according to intended transfemoral or transthoracic access and randomly assigned to undergo TAVR with the second-generation balloon-expandable SAPIEN XT valve or surgical aortic-valve replacement. The trial showed that TAVR was noninferior to surgery with respect to the primary outcome of death from any cause or disabling stroke at 2 years. 3Lire moins >
Lire la suite >To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement in the long term. Makkar et al. examined this question and report in this issue of the Journal the 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial, 2 which involved patients at intermediate surgical risk. A total of 2032 patients were stratified according to intended transfemoral or transthoracic access and randomly assigned to undergo TAVR with the second-generation balloon-expandable SAPIEN XT valve or surgical aortic-valve replacement. The trial showed that TAVR was noninferior to surgery with respect to the primary outcome of death from any cause or disabling stroke at 2 years. 3Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Source :
Fichiers
- document
- Accès libre
- Accéder au document
- Access%20provided%20by%20evb%20158.pdf
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Access%20provided%20by%20evb%20158.pdf
- Accès libre
- Accéder au document